We can’t show the full text here under this license. Use the link below to read it at the source.
Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review
Fatty Liver Disease Linked to Metabolism Problems and Heart Disease Risk: A Complete Review
AI simplified
Abstract
(MASLD) is strongly associated with (CVD).
- There is an increasing prevalence of MASLD globally.
- Different terminologies for fatty liver disease may affect cardiovascular risk assessment.
- Pathophysiological mechanisms connecting MASLD and CVD are explored.
- MASLD may influence traditional cardiovascular risk factors.
- Noninvasive imaging techniques and biomarkers are relevant for assessing cardiovascular risk in MASLD patients.
- The review provides insights into clinical management and prevention strategies related to MASLD and CVD.
AI simplified
Key numbers
25%
Global Prevalence of
Current estimate of prevalence worldwide.
38%
Projected Prevalence by 2023
Expected increase in prevalence by 2023.
70%
Risk in Patients
Percentage of T2DM patients who present with .